First Time Loading...
N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 13.7 CNY 5.14% Market Closed
Updated: May 5, 2024
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
/
Income Statement
/
Operating Income

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Operating Income Peer Comparison

Comparables:
H
3692
600436
600276
000538
C
300765

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Operating Income
¥1.1B
CAGR 3-Years
6%
CAGR 5-Years
18%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
¥3.7B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Income
¥3.3B
CAGR 3-Years
22%
CAGR 5-Years
22%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
¥3.6B
CAGR 3-Years
-17%
CAGR 5-Years
-3%
CAGR 10-Years
10%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
¥3.7B
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
6%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Operating Income
¥787.7m
CAGR 3-Years
32%
CAGR 5-Years
24%
CAGR 10-Years
N/A

See Also

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Operating Income?
Operating Income
1.1B CNY

Based on the financial report for Sep 30, 2023, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Operating Income amounts to 1.1B CNY.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
18%

Over the last year, the Operating Income growth was -7%. The average annual Operating Income growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 6% over the past three years , 18% over the past five years .

ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.